Stockscreener 앱 받기
103.24
0.01%
0.010
전일 마감가:
$103.23
열려 있는:
$103.225
하루 거래량:
2.12M
Relative Volume:
0.42
시가총액:
$19.61B
수익:
$3.08B
순이익/손실:
$-986.58M
주가수익비율:
-19.42
EPS:
-5.3172
순현금흐름:
$292.08M
1주 성능:
+0.06%
1개월 성능:
+0.97%
6개월 성능:
+129.88%
1년 성능:
+104.07%
1일 변동 폭
$103.15
$103.42
1주일 범위
$103.06
$103.54
52주 변동 폭
$38.81
$103.54
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.24 | 19.61B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Illinois Municipal Retirement Fund Boosts Stake in Exact Sciences Corporation $EXAS - MarketBeat
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Exact Sciences: Q4 Earnings Snapshot - kens5.com
Exact Sciences (EXAS) Surpasses Q4 Revenue Expectations - GuruFocus
Exact Sciences Q4 Loss Narrows, Revenue Rises - marketscreener.com
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Corp. Reports Record Fourth Quarter and Full Year 2025 Results - TradingView
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results - Business Wire
Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer - Yahoo Finance
Exact Sciences: Fourth Quarter Earnings Overview - Bitget
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - GlobeNewswire Inc.
Alger Mid Cap 40 ETF Q4 2025 Portfolio Update - Seeking Alpha
Exact Sciences Corporation (NASDAQ:EXAS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Take Profit: Will Exact Sciences Corporation benefit from green energy policiesLayoff News & Technical Buy Zone Confirmation - baoquankhu1.vn
Aug PreEarnings: Will Exact Sciences Corporation outperform its industry peersQuarterly Market Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Allianz Asset Management GmbH Makes New Investment in Exact Sciences Corporation $EXAS - MarketBeat
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Magazine
Exact Sciences (NASDAQ:EXAS) Sets New 12-Month HighTime to Buy? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (NasdaqNFBK), Coterra Energy Inc. (NYSECTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – - ChartMill
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? - Finviz
Exact Sciences Milestone In Breast Cancer Genomics And What It Means For EXAS - Yahoo Finance
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test - Law360
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent - The AI Journal
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
The Truth About Exact Sciences Corp: Is This Cancer-Test Stock Quietly Going Viral or About to Flop? - AD HOC NEWS
Principal Financial Group Inc. Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
C WorldWide Group Holding A S Has $46.97 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS Shares Sold by Heritage Investors Management Corp - MarketBeat
Medicare coverage pathway established for multi-cancer detection tests By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Applauds Medicare Coverage Pathway for Can - GuruFocus
Medicare coverage pathway established for multi-cancer detection tests - Investing.com
Exact Sciences welcomes Medicare coverage pathway for multi-cancer tests - StreetInsider
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests - Business Wire
Exact Sciences (NASDAQ:EXAS) Hits New 12-Month HighShould You Buy? - MarketBeat
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Pa - GuruFocus
Exact Sciences stock hits 52-week high at $102.69 - Investing.com
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide - Business Wire
Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 - Insider Monkey
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Bear Alert: Is Exact Sciences Corporation showing insider buyingWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal - Yahoo Finance UK
Freedom Capital Markets upgrades Abbott Labs stock rating to Buy on Exact Sciences deal - Investing.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement - Insider Monkey
EFG Asset Management North America Corp. Purchases 12,900 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Baillie Gifford & Co. Lowers Holdings in Exact Sciences Corporation $EXAS - MarketBeat
A Look At Exact Sciences (EXAS) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Is It Time To Reassess Exact Sciences (EXAS) After Its Strong One Year Share Price Run? - simplywall.st
Lobbying Update: $420,000 of EXACT SCIENCES lobbying was just disclosed - Quiver Quantitative
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이그젝트 사이 주식 (EXAS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Dec 23 '25 |
Option Exercise |
0.00 |
73,080 |
0 |
66,487 |
| Condella Sarah | EVP, Human Resources |
Dec 23 '25 |
Option Exercise |
0.00 |
47,208 |
0 |
118,059 |
| Herriott James | SVP, General Counsel & Sec |
Dec 23 '25 |
Option Exercise |
0.00 |
33,780 |
0 |
32,934 |
| Bloomer Aaron | EVP, Chief Financial Officer |
Dec 23 '25 |
Option Exercise |
0.00 |
63,099 |
0 |
59,571 |
| ORVILLE JACOB A | EVP, GM, Screening |
Nov 19 '25 |
Sale |
75.00 |
5,000 |
375,000 |
23,237 |
| Herriott James | SVP, General Counsel & Sec |
Nov 19 '25 |
Sale |
70.00 |
1,000 |
70,000 |
11,585 |
0.00%
1.13%
자본화:
|
볼륨(24시간):